Evidence map›Paper›PMID 26918062›Full record

ArticleJournal of Cancer2016

Serum Unsaturated Free Fatty Acids: A Potential Biomarker Panel for Early-Stage Detection of Colorectal Cancer.

Yaping Zhang, Chengyan He, Ling Qiu, Yanmin Wang, Xuzhen Qin, Yujie Liu, Zhili Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. A high serum-free fatty acid level is associated with cancer.Journal of cancer research and clinical oncology · 2020
    Article
  17. Review
  18. Review
  19. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.International journal of molecular sciences · 2019
    Review
  20. Targeting Long Chain Acyl-CoA Synthetases for Cancer Therapy.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yaping Zhang1. Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, China;
Chengyan He2. Clinical Lab Diagnosis, China-Japan Union Hospital, Jilin University, Changchun, China;
Ling Qiu3. Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;
Yanmin Wang4. Department of Clinical Laboratory, Heze Municipal Hospital, Heze, China.
Xuzhen Qin3. Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;
Yujie Liu1. Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, China;
Zhili Li1. Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, China;
Chinese Academy of Medical Sciences & Peking Union Medical College · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo screen biomarkers to differentiate early-stage colorectal cancer (CRC) from benign colorectal disease (BCD) and healthy controls. MATERIALS &

methodsQuantitative and qualitative analysis of C16:1, C18:3, C18:2, C18:1, C20:4, and C22:6 in 185 healthy controls, 55 patients with BCD, and 139 patients with CRC was performed. Comparisons of their levels in between CRC patients, BCD patients, and healthy controls were performed using Mann-Whitney U test.

resultsSerum levels of C16:1, C18:3, C18:2, C18:1, C20:4, and C22:6 in CRC patients were significantly decreased compared with healthy controls and BCD patients. A combination of C16:1, C18:2, C20:4, and C22:6 has excellent diagnostic performance to differentiate early-stage CRC patients from healthy controls plus BCD patients, with an AUC of 0.926, a sensitivity of 84.6%, and a specificity of 89.8%.

conclusionsSerum levels of C16:1, C18:2, C20:4, and C22:6 could be diagnostic indicators of early-stage CRC patients.

Indexed as

biomarker panelcolorectal cancer.early detectionserumunsaturated free fatty acids

Identifiers

PMID26918062
PMCPMC4749369
OpenAlexW2280589513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.